Zerion

Do you have problems with insoluble drug candidates? This new webinar highlights the use of a solubility enhancing technology that can improve performance and increase bioavailability.

https://www.pharmtech.com/pt_w/solubility-enhancing-technology

Solubility remains a huge problem in the pharmaceutical industry. The Dispersome® technology is a new solubility enhancing technology and is a compelling alternative to other solubility enhancing technologies, simply because Dispersomes® provide a better performance with respect to solubility and bioavailability increase, even of practically insoluble drugs. Dispersomes® is a drug formulation technology that is based on the use of Pharma Grade Beta-lactoglobulin (BLG) as a novel pharmaceutical excipient. The Dispersome® technology stabilizes the drug into an amorphous and highly soluble form. The webinar will give a comprehensive overview on the recent developments with the Dispersome® technology. These cover the scientific insights gained, the status on the novel excipient BLG, as well as case studies for several programs.

Understand how the Dispersome technology enhances drug solubility

Learn from case studies how it works well across many type of small molecules

Pharmaceutical researchers and scientists

CMC experts on oral drug delivery & formulation

Business development, portfolio management and technology licensing experts

 is CSO and co-founder of Zerion Pharma A/S, which was established in January 2019 in Copenhagen, Denmark. He is author of more than 120 peer reviewed publications and patents. Prior to his role in Zerion Pharma, Dr. Korbinian Löbmann had an appointment as Assoc. Prof. with a research focus on solid state pharmacteutics at the University of Copenhagen, Denmark. He received his PhD degree from the School of Pharmacy, University of Otago, Dunedin, New Zealand in 2013.


Webcasts

Webinar Date/Time: Tue, Jan 30, 2024 9:00 AM EST





Zerion Pharma R&D Day – Dispersome® Drug Formulation Platform

https://www.pharmtech.com/pt_w/Dispersome

Poor drug solubility is one of the most challenging issues in drug development. Up to 90 % of all newly discovered drugs show insufficient aqueous solubility in their crystalline form, resulting in too low bioavailability, because the drug must dissolve in order to be absorbed and reach its pharmacological target. Many promising drug candidates are thus discontinued during early-stage development due to poor bioavailability resulting from low solubility.

The Dispersome® technology is a novel solubility enhancing approach that is based on using the protein beta-lactoglobulin (BLG) as novel pharmaceutical excipient. By mixing a drug compound with this by-product from cheese production, a unique amorphous composition of small molecule drugs and proteins is obtained.

The technology has been shown to dramatically increase the solubility and bioavailability of poorly-soluble drugs, which is demonstrated by case studies. These co-amorphous drug-BLG formulations can be manufactured by spray drying. In this presentation, a roadmap of the spray-drying development process, including solution preparation, spray drying and secondary drying, will be covered. Considerations are made on both, formulation and manufacturing processes, all of which are important to bring these new formulations from the laboratory to production scale.

A focus will be given to the importance of lab-scale familiarization and supporting studies throughout the development process as well as how computational, statistical tools combined with prior knowledge can be capitalized to reduce risk while maximizing time and resources.



Innovation in bioavailability enhancement using BLG

Amorphous stabilization using proteins as excipients

How formulations can be scaled up to meet commercial supply demand



This webinar is targeted at scientists and managers working in the field of pre-formulation, formulation, and CMC. The webinar has a focus on solid oral dosage form development for poorly-soluble drugs.

Pedro Valente
Oral Drug Product Development
Hovione

Dr. Pedro Valente is the director of oral drug product development at Hovione R&D, specializing in formulation, particle engineering, and process development of pharmaceutical drug products for oral delivery. Prior to joining Hovione as an R&D scientist in 2015, Pedro worked as aerothermodynamics engineer at Volvo Aero Corp. in Sweden (now GKN aerospace) and later on was an invited lecturer and researcher at the University of Lisbon, covering the areas of fluid mechanics and turbulence. Valente holds a PhD from Imperial College London (UK) in aeronautics and MScs from the U. Lisbon, Portugal (Mech. Eng.), and from Chalmers Technical University, Sweden (fluid dynamics and turbulence).

Dr. Korbinian Löbmann is the CSO at Zerion Pharma, a university spin-out that he co-founded in 2019. He has more than 10 years of experience in solid formulation and dosage form development, including preformulation, formulation, processing, and manufacturing together with the relevant solid-state characterization and quality control. This includes the development of new enabling formulation strategies for poorly soluble drugs using amorphous drug delivery systems. Löbmann received his PhD in pharmaceutical sciences in 2013 from the University of Otago, New Zealand and then joined the University of Copenhagen, where he was appointed assoc. prof. in 2017. He has authored more than 100 peer-reviewed papers and patents.

Thursday, September 8, 2022 at 11am EDT; 4pm GMT; 5pm CEST
This webinar will highlight the new solubility enhancing Dispersome® technology, which is based on the amorphous stabilization of a given drug using the protein beta-lactoglobulin (BLG) as novel pharmaceutical excipient. Several relevant case studies are presented to showcase the potential of this new technology. Subsequently, the webinar provides a roadmap on how these formulations can be manufactured on a commercial scale. The webinar will also cover the manufacturing of the formulations.

Zerion

Articles